Pedf derived peptides affect colorectal cancer cell lines resistance and tumour re-growth capacity

Honrubia Gómez, Paloma and López Garrido, María Pilar and Gil Gas, Carmen and Sánchez Sánchez, José and Álvarez Simón, Carmen and Cuenca Escalona, Jorge and Ferrer Pérez, Ana and Arias, Enrique and Moreno, Raúl and Sánchez Sánchez, Francisco and Ramírez Castillejo, María del Carmen (2019). Pedf derived peptides affect colorectal cancer cell lines resistance and tumour re-growth capacity. "Oncotarget", v. 10 (n. 31); pp. 2973-2986. ISSN 1949-2553. https://doi.org/10.18632/oncotarget.26085.

Description

Title: Pedf derived peptides affect colorectal cancer cell lines resistance and tumour re-growth capacity
Author/s:
  • Honrubia Gómez, Paloma
  • López Garrido, María Pilar
  • Gil Gas, Carmen
  • Sánchez Sánchez, José
  • Álvarez Simón, Carmen
  • Cuenca Escalona, Jorge
  • Ferrer Pérez, Ana
  • Arias, Enrique
  • Moreno, Raúl
  • Sánchez Sánchez, Francisco
  • Ramírez Castillejo, María del Carmen
Item Type: Article
Título de Revista/Publicación: Oncotarget
Date: April 2019
ISSN: 1949-2553
Volume: 10
Subjects:
Freetext Keywords: colorectal cancer stem cells; cancer initiating cells; relapse; self-renewal inhibition; PEDF
Faculty: E.T.S. de Ingeniería Agronómica, Alimentaria y de Biosistemas (UPM)
Department: Biotecnología - Biología Vegetal
Creative Commons Licenses: Recognition - No derivative works - Non commercial

Full text

[img]
Preview
PDF - Requires a PDF viewer, such as GSview, Xpdf or Adobe Acrobat Reader
Download (1MB) | Preview

Abstract

Relapse after chemotherapy treatment depends on the cancer initiating cells (CICs). PEDF (Pigmented Epithelium Derived Factor) is an anti-angiogenic, neurotrophic and self-renewal regulator molecule, also involved in CICs biology. Acute and chronic exposition of colon cancer cell lines to CT/CTE PEDF-derived peptides decreased drug-resistance to conventional colorectal cancer treatments, such as oxaliplatin or irinotecan. We confirmed a reduction in the irinotecan and oxaliplatin IC50 doses for all tested tumour cell lines. After xenograft transplantation, CT/CTE treatments also produced a reduction in resistance to conventional chemotherapy treatments as in culture-assays. Metastatic capacity of these treated cell lines was so depleted. The PEDF signaling pathway could be a future therapeutic tool for use as an adjuvant therapy that decreases IC50 dosis, adverse effects and treatment costs. This pathway could also be involved in an increase of the time relapse in patients, decreased tumourigenicity, and decreased capacity to produce metastasis.

Funding Projects

TypeCodeAcronymLeaderTitle
Universidad Politécnica de MadridPINV-18-KOIZCD-102- T2D5FOUnspecifiedRamírez Castillejo, María del CarmenUnspecified

More information

Item ID: 63828
DC Identifier: http://oa.upm.es/63828/
OAI Identifier: oai:oa.upm.es:63828
DOI: 10.18632/oncotarget.26085
Official URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6508205/pdf/oncotarget-10-2973.pdf
Deposited by: Memoria Investigacion
Deposited on: 17 Sep 2020 17:20
Last Modified: 17 Sep 2020 17:20
  • Logo InvestigaM (UPM)
  • Logo GEOUP4
  • Logo Open Access
  • Open Access
  • Logo Sherpa/Romeo
    Check whether the anglo-saxon journal in which you have published an article allows you to also publish it under open access.
  • Logo Dulcinea
    Check whether the spanish journal in which you have published an article allows you to also publish it under open access.
  • Logo de Recolecta
  • Logo del Observatorio I+D+i UPM
  • Logo de OpenCourseWare UPM